Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 169

1.

Early Palliative Care: A Necessary Intervention for Patients Ineligibile to Approved Potentially Life-saving CAR T-cell Therapy.

Potenza L, Luppi M, Efficace F, Bruera E, Bandieri E.

Clin Lymphoma Myeloma Leuk. 2019 Dec 23. pii: S2152-2650(19)32216-5. doi: 10.1016/j.clml.2019.12.004. [Epub ahead of print] No abstract available.

PMID:
31928952
2.

Consistency matters: measurement invariance of the EORTC QLQ-C30 questionnaire in patients with hematologic malignancies.

Sommer K, Cottone F, Aaronson NK, Fayers P, Fazi P, Rosti G, Angelucci E, Gaidano G, Venditti A, Voso MT, Baccarani M, Vignetti M, Efficace F.

Qual Life Res. 2020 Mar;29(3):815-823. doi: 10.1007/s11136-019-02369-5. Epub 2019 Nov 28.

PMID:
31782016
3.

Time to deterioration in cancer randomized clinical trials for patient-reported outcomes data: a systematic review.

Charton E, Cuer B, Cottone F, Efficace F, Touraine C, Hamidou Z, Fiteni F, Bonnetain F, Woronoff-Lemsi MC, Bascoul-Mollevi C, Anota A.

Qual Life Res. 2019 Nov 27. doi: 10.1007/s11136-019-02367-7. [Epub ahead of print] Review.

PMID:
31776827
4.

Inclusion of older patients with cancer in randomised controlled trials with patient-reported outcomes: a systematic review.

Sparano F, Aaronson NK, Sprangers MAG, Fayers P, Pusic A, Kieffer JM, Cottone F, Rees J, Pezold M, Anota A, Charton E, Vignetti M, Wan C, Blazeby J, Efficace F.

BMJ Support Palliat Care. 2019 Dec;9(4):451-463. doi: 10.1136/bmjspcare-2019-001902. Epub 2019 Nov 12. Review.

PMID:
31719051
5.

Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies.

Efficace F, Cottone F, Sommer K, Kieffer J, Aaronson N, Fayers P, Groenvold M, Caocci G, Lo Coco F, Gaidano G, Niscola P, Baccarani M, Rosti G, Venditti A, Angelucci E, Fazi P, Vignetti M, Giesinger J.

Value Health. 2019 Nov;22(11):1303-1310. doi: 10.1016/j.jval.2019.06.004. Epub 2019 Aug 7.

PMID:
31708068
6.

Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research.

Giesinger JM, Loth FLC, Aaronson NK, Arraras JI, Caocci G, Efficace F, Groenvold M, van Leeuwen M, Petersen MA, Ramage J, Tomaszewski KA, Young T, Holzner B; EORTC Quality of Life Group.

J Clin Epidemiol. 2020 Feb;118:1-8. doi: 10.1016/j.jclinepi.2019.10.003. Epub 2019 Oct 19.

7.

Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial.

Cicconi L, Platzbecker U, Avvisati G, Paoloni F, Thiede C, Vignetti M, Fazi P, Ferrara F, Divona M, Albano F, Efficace F, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Annibali O, Wattad M, Lubbert M, Brandts CH, Hanel M, Rollig C, Schmitz N, Link H, Frairia C, Fozza C, Maria D'Arco A, Di Renzo N, Cortelezzi A, Fabbiano F, Dohner K, Ganser A, Dohner H, Amadori S, Mandelli F, Voso MT, Ehninger G, Schlenk RF, Lo-Coco F.

Leukemia. 2019 Oct 14. doi: 10.1038/s41375-019-0589-3. [Epub ahead of print] No abstract available.

PMID:
31611624
8.

Quality of life and CAR-T cell therapy in children, adolescents, and young adults with haematological malignancies.

Efficace F, Vignetti M.

Lancet Oncol. 2019 Dec;20(12):1625-1626. doi: 10.1016/S1470-2045(19)30641-2. Epub 2019 Oct 9. No abstract available.

PMID:
31606418
9.

Thresholds for clinical importance were defined for the European Organisation for Research and Treatment of Cancer Computer Adaptive Testing Core-an adaptive measure of core quality of life domains in oncology clinical practice and research.

Giesinger JM, Loth FLC, Aaronson NK, Arraras JI, Caocci G, Efficace F, Groenvold M, van Leeuwen M, Petersen MA, Ramage J, Tomaszewski KA, Young T, Holzner B; EORTC Quality of Life Group.

J Clin Epidemiol. 2020 Jan;117:117-125. doi: 10.1016/j.jclinepi.2019.09.028. Epub 2019 Oct 5.

10.

Patient-reported outcomes in randomised clinical trials of bladder cancer: an updated systematic review.

Van Hemelrijck M, Sparano F, Josephs D, Sprangers M, Cottone F, Efficace F.

BMC Urol. 2019 Sep 14;19(1):86. doi: 10.1186/s12894-019-0518-9.

11.

Development and validation of a patient-reported outcome tool to assess cancer-related financial toxicity in Italy: a protocol.

Riva S, Bryce J, De Lorenzo F, Del Campo L, Di Maio M, Efficace F, Frontini L, Giannarelli D, Gitto L, Iannelli E, Jommi C, Montesarchio V, Traclò F, Vaccaro CM, Gallo C, Perrone F.

BMJ Open. 2019 Sep 9;9(9):e031485. doi: 10.1136/bmjopen-2019-031485.

12.

Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy.

Efficace F, Stagno F, Iurlo A, Breccia M, Cottone F, Bonifacio M, Abruzzese E, Castagnetti F, Caocci G, Crugnola M, Capodanno I, Martino B, Tiribelli M, Patriarca A, Gozzini A, Pregno P, Saussele S, Cascavilla N, Fozza C, Bergamaschi M, Binotto G, Vignetti M, Rosti G.

Leukemia. 2020 Feb;34(2):488-498. doi: 10.1038/s41375-019-0563-0. Epub 2019 Sep 2.

PMID:
31477798
13.

Towards the integration of patient-reported outcomes into the global clinical management of multiple myeloma.

Niscola P, Scaramucci L, Efficace F.

Expert Rev Hematol. 2019 Sep;12(9):703-705. doi: 10.1080/17474086.2019.1645005. Epub 2019 Aug 28. No abstract available.

PMID:
31317793
14.

Physical activity and health-related quality of life in multiple myeloma survivors: the PROFILES registry.

Servadio M, Cottone F, Sommer K, Oerlemans S, van de Poll-Franse L, Efficace F.

BMJ Support Palliat Care. 2019 Jun 28. pii: bmjspcare-2018-001755. doi: 10.1136/bmjspcare-2018-001755. [Epub ahead of print]

PMID:
31253733
15.

Early versus delayed palliative/supportive care in advanced cancer: an observational study.

Bandieri E, Banchelli F, Artioli F, Mucciarini C, Razzini G, Cruciani M, Potenza L, D'Amico R, Efficace F, Bruera E, Luppi M.

BMJ Support Palliat Care. 2019 Jun 14. pii: bmjspcare-2019-001794. doi: 10.1136/bmjspcare-2019-001794. [Epub ahead of print]

PMID:
31201152
16.

Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice.

Scalzulli E, Molica M, Alunni Fegatelli D, Colafigli G, Rizzo L, Mancini M, Efficace F, Latagliata R, Foà R, Breccia M.

Ann Hematol. 2019 Aug;98(8):1919-1925. doi: 10.1007/s00277-019-03724-9. Epub 2019 Jun 5.

PMID:
31168652
17.

Assessing Financial Toxicity in Patients With Cancer: Moving Away From a One-Size-Fits-All Approach.

Perrone F, Di Maio M, Efficace F, Gallo C, Giannarelli D, Montesarchio V, Riva S.

J Oncol Pract. 2019 Aug;15(8):460-461. doi: 10.1200/JOP.19.00200. Epub 2019 May 24. No abstract available.

PMID:
31125283
18.

Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients.

Baron F, Efficace F, Cannella L, Willemze R, Vignetti M, Muus P, Marie JP, Ferrero D, Fazi P, La Sala E, Bourhis JH, Fabbiano F, Bosi A, Sborgia M, Martinelli G, Wittnebel S, Trisolini S, Petti MC, Halkes CJM, van der Velden WJFM, de Witte T, Amadori S, Zittoun RA, Suciu S.

Haematologica. 2020 Jan;105(1):e13-e16. doi: 10.3324/haematol.2019.221333. Epub 2019 May 16. No abstract available.

19.

Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life.

Molica M, Colafigli G, Scalzulli E, Alunni Fegatelli D, Chiatamone Ranieri S, Rizzo L, Diverio D, Efficace F, Latagliata R, Foà R, Breccia M.

Ann Hematol. 2019 Aug;98(8):1891-1904. doi: 10.1007/s00277-019-03706-x. Epub 2019 May 11.

PMID:
31079264
20.

Pain and related complaints in patients with acute leukemia: time for simultaneous care in hemato-oncology.

Niscola P, Tendas A, Mazzone C, Efficace F.

Support Care Cancer. 2019 Aug;27(8):2755-2756. doi: 10.1007/s00520-019-04743-y. Epub 2019 Apr 13.

PMID:
31053971
21.

Systematic Evaluation of Patient-Reported Outcome Protocol Content and Reporting in Cancer Trials.

Kyte D, Retzer A, Ahmed K, Keeley T, Armes J, Brown JM, Calman L, Gavin A, Glaser AW, Greenfield DM, Lanceley A, Taylor RM, Velikova G, Brundage M, Efficace F, Mercieca-Bebber R, King MT, Turner G, Calvert M.

J Natl Cancer Inst. 2019 Nov 1;111(11):1170-1178. doi: 10.1093/jnci/djz038.

22.

Health-related Quality of Life in Cutaneous Lymphomas: Past, Present and Future.

Jonak C, Porkert S, Oerlemans S, Papadavid E, Molloy K, Lehner-Baumgartner E, Cozzio A, Efficace F, Scarisbrick J.

Acta Derm Venereol. 2019 Jun 1;99(7):640-646. doi: 10.2340/00015555-3171. Review.

23.

Clinician-reported symptomatic adverse events in cancer trials: are they concordant with patient-reported outcomes?

Sparano F, Aaronson NK, Cottone F, Piciocchi A, La Sala E, Anota A, Deliu N, Kieffer JM, Efficace F.

J Comp Eff Res. 2019 Apr;8(5):279-288. doi: 10.2217/cer-2018-0092. Epub 2019 Mar 6.

PMID:
30838883
24.

Propensity score methods and regression adjustment for analysis of nonrandomized studies with health-related quality of life outcomes.

Cottone F, Anota A, Bonnetain F, Collins GS, Efficace F.

Pharmacoepidemiol Drug Saf. 2019 May;28(5):690-699. doi: 10.1002/pds.4756. Epub 2019 Feb 19.

PMID:
30784132
25.

Modeling strategies to improve parameter estimates in prognostic factors analyses with patient-reported outcomes in oncology.

Cottone F, Deliu N, Collins GS, Anota A, Bonnetain F, Van Steen K, Cella D, Efficace F.

Qual Life Res. 2019 May;28(5):1315-1325. doi: 10.1007/s11136-018-02097-2. Epub 2019 Jan 18.

PMID:
30659449
26.

Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia.

Efficace F, Breccia M, Avvisati G, Cottone F, Intermesoli T, Borlenghi E, Carluccio P, Rodeghiero F, Fabbiano F, Luppi M, Romani C, Sborgia M, D'Ardia S, Nobile F, Cantore N, Crugnola M, Nadali G, Vignetti M, Amadori S, Lo Coco F.

Leukemia. 2019 Jul;33(7):1598-1607. doi: 10.1038/s41375-018-0325-4. Epub 2018 Dec 20.

PMID:
30573776
27.

Distribution- and anchor-based methods to determine the minimally important difference on patient-reported outcome questionnaires in oncology: a structured review.

Ousmen A, Touraine C, Deliu N, Cottone F, Bonnetain F, Efficace F, Brédart A, Mollevi C, Anota A.

Health Qual Life Outcomes. 2018 Dec 11;16(1):228. doi: 10.1186/s12955-018-1055-z. Review.

28.

International phase IV validation study of an EORTC quality of life questionnaire for testicular cancer patients: the EORTC QLQ-TC26.

Sztankay M, Aaronson NK, Arraras JI, Basso U, Bumbasirevic U, Efficace F, Giesinger JM, Johnson CD, van Leeuwen M, Oberguggenberger AS, Sosnowski R, Young T, Holzner B; European Organisation for Research and Treatment of Cancer Quality of Life Group (EORTC QLG).

BMC Cancer. 2018 Nov 12;18(1):1104. doi: 10.1186/s12885-018-5036-8.

29.

Time for patient reported outcomes assessment in routine hematology practice: the case of chronic myeloid leukemia.

Efficace F, Cottone F.

Expert Rev Hematol. 2019 Jan;12(1):1-3. doi: 10.1080/17474086.2019.1547189. Epub 2018 Nov 14. No abstract available.

PMID:
30411646
30.

Evaluating methodological quality of Prognostic models Including Patient-reported HeAlth outcomes iN oncologY (EPIPHANY): a systematic review protocol.

Deliu N, Cottone F, Collins GS, Anota A, Efficace F.

BMJ Open. 2018 Oct 24;8(10):e025054. doi: 10.1136/bmjopen-2018-025054.

31.

How should we assess patient-reported outcomes in the onco-hematology clinic?

Cannella L, Efficace F, Giesinger J.

Curr Opin Support Palliat Care. 2018 Dec;12(4):522-529. doi: 10.1097/SPC.0000000000000386. Review.

PMID:
30239387
32.

A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: the CLARITY study protocol.

Efficace F, Boccadoro M, Palumbo A, Petrucci MT, Cottone F, Cannella L, Zamagni E, Niscola P, Kyriakou C, Caravita T, Offidani M, Mandelli F, Cavo M.

Health Qual Life Outcomes. 2018 Jun 18;16(1):127. doi: 10.1186/s12955-018-0953-4.

33.

Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib.

Breccia M, Efficace F, Iurlo A, Luciano L, Abruzzese E, Gozzini A, Pregno P, Tiribelli M, Rosti G, Minotti G.

Expert Opin Drug Saf. 2018 Jun;17(6):623-628. doi: 10.1080/14740338.2018.1480719. Epub 2018 May 30. Review.

PMID:
29845876
34.

Patient-reported outcome assessment in acute leukemias: Moving beyond the barriers.

Efficace F, Cottone F, Sparano F, Lo-Coco F.

Cancer. 2018 Jul 15;124(14):3066-3067. doi: 10.1002/cncr.31521. Epub 2018 Apr 30. No abstract available.

35.

Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis.

Caocci G, Mulas O, Annunziata M, Luciano L, Bonifacio M, Orlandi EM, Pregno P, Galimberti S, Russo Rossi A, Abruzzese E, Iurlo A, Martino B, Sgherza N, Binotto G, Castagnetti F, Gozzini A, Fozza C, Bocchia M, Sicuranza A, Stagno F, Efficace F, Usala E, De Gregorio F, Scaffidi L, Elena C, Pirillo F, Baratè C, Trawinska MM, Cattaneo D, Labate C, Gugliotta G, Molica M, Specchia G, La Nasa G, Foà R, Breccia M.

Am J Hematol. 2018 Jul;93(7):E159-E161. doi: 10.1002/ajh.25102. Epub 2018 Apr 28. No abstract available.

36.

Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study.

Stauder R, Yu G, Koinig KA, Bagguley T, Fenaux P, Symeonidis A, Sanz G, Cermak J, Mittelman M, Hellström-Lindberg E, Langemeijer S, Holm MS, Mądry K, Malcovati L, Tatic A, Germing U, Savic A, van Marrewijk C, Guerci-Bresler A, Luño E, Droste J, Efficace F, Smith A, Bowen D, de Witte T.

Leukemia. 2018 Jun;32(6):1380-1392. doi: 10.1038/s41375-018-0089-x. Epub 2018 Mar 6.

37.

Patient-reported outcomes in relapsed/refractory multiple myeloma: a systematic review.

Sparano F, Cavo M, Niscola P, Caravita T, Efficace F.

Support Care Cancer. 2018 Jul;26(7):2075-2090. doi: 10.1007/s00520-018-4137-x. Epub 2018 Mar 20.

PMID:
29560502
38.

Sexual health in patients with hematological malignancies: a neglected issue.

Niscola P, Efficace F, Abruzzese E.

Support Care Cancer. 2018 Jun;26(6):1699-1701. doi: 10.1007/s00520-018-4124-2. Epub 2018 Mar 3.

PMID:
29502153
39.

Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.

Efficace F, Castagnetti F, Martino B, Breccia M, D'Adda M, Angelucci E, Stagno F, Cottone F, Malato A, Trabacchi E, Capalbo SF, Gobbi M, Visani G, Salvucci M, Capodanno I, Tosi P, Tiribelli M, Scortechini AR, Levato L, Maino E, Binotto G, Gugliotta G, Vignetti M, Baccarani M, Rosti G.

Cancer. 2018 May 15;124(10):2228-2237. doi: 10.1002/cncr.31323. Epub 2018 Mar 2.

40.

Evaluation of patient-reported outcome protocol content and reporting in UK cancer clinical trials: the EPiC study qualitative protocol.

Retzer A, Keeley T, Ahmed K, Armes J, Brown JM, Calman L, Copland C, Efficace F, Gavin A, Glaser A, Greenfield DM, Lanceley A, Taylor RM, Velikova G, Brundage M, Mercieca-Bebber R, King MT, Calvert M, Kyte D.

BMJ Open. 2018 Feb 3;8(2):e017282. doi: 10.1136/bmjopen-2017-017282.

41.

Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes.

Efficace F, Cottone F, Abel G, Niscola P, Gaidano G, Bonnetain F, Anota A, Caocci G, Cronin A, Fianchi L, Breccia M, Stauder R, Platzbecker U, Palumbo GA, Luppi M, Invernizzi R, Bergamaschi M, Borin L, Di Tucci AA, Zhang H, Sprangers M, Vignetti M, Mandelli F.

Cancer. 2018 Mar 15;124(6):1251-1259. doi: 10.1002/cncr.31193. Epub 2017 Dec 12.

42.

Early Palliative Care in Patients With Hematological Malignancies: Where Do We Go From Here?

Niscola P, Tendas A, Efficace F.

J Pain Symptom Manage. 2018 Apr;55(4):e1-e2. doi: 10.1016/j.jpainsymman.2017.11.023. Epub 2017 Nov 28. No abstract available.

PMID:
29191722
43.

International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia.

van de Poll-Franse L, Oerlemans S, Bredart A, Kyriakou C, Sztankay M, Pallua S, Daniëls L, Creutzberg CL, Cocks K, Malak S, Caocci G, Molica S, Chie W, Efficace F; EORTC Quality of Life Group.

Qual Life Res. 2018 Feb;27(2):333-345. doi: 10.1007/s11136-017-1718-y. Epub 2017 Nov 10.

44.

Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients.

Breccia M, Baccarani M, Rosti G, Cottone F, Cannella L, Guilhot F, Vignetti M, Efficace F.

Health Qual Life Outcomes. 2017 Oct 18;15(1):204. doi: 10.1186/s12955-017-0788-4.

45.

A cross-cultural convergent parallel mixed methods study of what makes a cancer-related symptom or functional health problem clinically important.

Giesinger JM, Aaronson NK, Arraras JI, Efficace F, Groenvold M, Kieffer JM, Loth FL, Petersen MA, Ramage J, Tomaszewski KA, Young T, Holzner B; EORTC Quality of Life Group.

Psychooncology. 2018 Feb;27(2):548-555. doi: 10.1002/pon.4548. Epub 2017 Sep 21.

PMID:
28857424
46.

Patient-reported outcomes in hematology: is it time to focus more on them in clinical trials and hematology practice?

Efficace F, Gaidano G, Lo-Coco F.

Blood. 2017 Aug 17;130(7):859-866. doi: 10.1182/blood-2017-03-737403. Epub 2017 Jul 10. Review.

PMID:
28694324
47.

Are chronic myeloid leukemia patients ready to stop long-term treatment?

Breccia M, Efficace F.

Leuk Lymphoma. 2017 Dec;58(12):2976-2978. doi: 10.1080/10428194.2017.1330476. Epub 2017 May 23. No abstract available.

PMID:
28535695
48.

International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer.

van Leeuwen M, Kieffer JM, Efficace F, Fosså SD, Bolla M, Collette L, Colombel M, De Giorgi U, Holzner B, van de Poll-Franse LV, van Poppel H, White J, de Wit R, Osanto S, Aaronson NK; European Organisation for Research and Treatment of Cancer Quality of Life Group; Genito-Urinary Cancers Group and Radiation Oncology Group; and the NCRN Testis Clinical Studies Group.

Health Qual Life Outcomes. 2017 May 11;15(1):97. doi: 10.1186/s12955-017-0670-4.

49.

Socioeconomic burden of participation in clinical trials in patients with myeloproliferative neoplasms.

Goel S, Paoli C, Iurlo A, Pereira A, Efficace F, Barbui T, Tefferi A, Vannucchi AM, Cervantes F.

Eur J Haematol. 2017 Jul;99(1):36-41. doi: 10.1111/ejh.12887. Epub 2017 May 5.

PMID:
28370510
50.

The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors.

Efficace F, Cannella L.

Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):170-179. Review.

Supplemental Content

Loading ...
Support Center